Our Commitment
-
We’re committed to making sustainable business decisions
for the betterment of society, global health, and the planetSamsung Biologics is pursuing its mission to create a better world with high-quality biopharmaceuticals through a global logistics supply chain and comprehensive social responsibilities, while building a basis for sustainability. As a response to climate change, Samsung Biologics will expand its eco-friendly investment in the production facilities and energy reduction in the business sites, while also engaging in the Carbon Disclosure Project (CDP).
Moreover, we will grow with the local community through various social contribution activities such as supporting the most vulnerable members of our local community, and fulfilling social environmental responsibilities by participating in the Korea National Institute for Bioprocessing Research & Training (K-NIBRT) to establish the Shared Growth Management. -
Samsung Biologics was awarded the 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets.
-
sustainable markets initiative
- Member of Sustainable Markets Initiative (led by The Former Prince of Wales)
-
Supply Chains Working Group championed by John Rim, CEO of Samsung Biologics
2022 Recipient of the Terra Carta Seal for commitment to sustainability
-
Member of Dow Jones Sustainability Indices Powered by the S&P Global CSA
- Listed by the DJSI World Index
-
For two consecutive years (2021 & 2022), ranking 2nd in the Life Science Tools & Services Sub-Industry index
-
ISO
- Obtained global ISO certifications
-
- - ISO 50001 (Energy Management)
- - ISO 45001 (Occupational Health and Safety Management)
- - ISO 14001 (Effective Environmental Management)
-
FROST SULLIVAN INSTITUTE
- 2022 Enlightened Growth Leadership Award
-
Recognized for ‘innovating to zero’
- - Zero global illness
- - Zero emissions
- - Zero workplace accidents
-
Frontier 1.5D
- Participant in the Frontier 1.5D initiative
-
Developing a climate risk management model as part of 2050 Carbon Neutral Strategy
-
CDP
- 2021 & 2022 B rating in CDP & “Honors Award” in carbon management sector by CDP awards
-
KCGS 한국기업지배구조원
- 2021 & 2022 Grade A in ESG comprehensive evaluation
-
Environmental A
Social management A+
Corporate governance A
-
ministry of gender equality and family
- “Best Family-Friendly Management” company for 8 consecutive years
Sustainable Supply Chain
therefore, we are committed to reducing the environmental impact of our operations and our products.
- Supplier decarbonization standards
-
While Samsung Biologics’ emissions from business sites (Scopes 1 & 2) account for 13%, 87% of emissions fall under indirect emissions (Scope 3) due to the nature of the CDMO business.
Samsung Biologics Carbon Footprint
- Upstream
-
86.4%(899,413 tCO2eq)
Purchased goods and services:53.0%
Capital goods: 30.9%
Others: 2.5%
Launch supplier initiatives and achieve Net Zero in the supply chain through emissions analysis
- Site
-
12.6%(130,930 tCO2eq)
Direct emissions (Scope 1): 4.2%
LNG: 4.1% / Fuel: 0.1%
Indirect emissions (Scope 2): 8.4%
Achieve Net Zero through reduction / replacement activities and transition to 100% renewable energy
- Downstream
-
1.0%(11,216 tCO2eq)
Investments: 0.6%
Downstream transportation and distribution: 0.4%
Achieve Net Zero across subsidiaries and clients through initiatives
Since 83.9% of our Scope 3 emissions comes from the supply chain, Samsung Biologics aims to establish a Net Zero Supply Chain Program, aligned with the Sustainable Markets Initiative’s efforts, to work more closely with our suppliers to reduce our overall impact.
To reach net zero by 2050 or earlier, we expect our partners to:- Set Net Zero targets
-
- · Set Net Zero targets aligned with the 1.5°C pathway (2050 or earlier).
- · Join climate initiatives such as SBTi and RE100 and verify the targets.
- Assess & disclose GHG emissions
-
- · Calculate Scope 1, 2 and 3 emissions.
- · Improve the accuracy through Life Cycle Assessments.
- · Disclose emissions and the status of climate change response via CDP or other global platforms.
- Participate in an annual survey
-
- · Participate in our survey to share annual emissions reduction performance.
- · Set standards for calculating the share of emissions related to Samsung Biologics (product-level LCA, etc.).
- Evaluating supplier sustainability
-
- Evaluation
-
We will continue to monitor the status of the supply chain’s climate change response through an Annual Survey and provide consultation opportunities to fulfill requirements and improve response levels.
We also invite our suppliers to allow us to conduct assessments and evaluations to increase our supply chain transparency and actively encourage participation in identifying areas of improvement.
- Benefits
-
Through our evaluation and assessment program, Samsung Biologics will offer more opportunities and benefits in new process development and supply chain selection to suppliers who actively engage in climate change response activities.
To fully integrate sustainability into our value chain, our suppliers’ participation is vital and will serve as an opportunity to further reinforce our connection with clients to build a healthier future for all.
Marketing Practices
Samsung Biologics endeavors that our marketing activities and materials to promote services and products comply with ethical, medical, and scientific standards as
well as applicable laws and regulations. When engaging with healthcare professionals, patients, and business partners, Samsung Biologics will abide by relevant industry
standards of conduct.